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| INTRODUC TI ON
Hepatocellular carcinoma (HCC) has high morbidity and death rates not only in China, where it, according to the latest report, was the fourth most common type of malignancy and the third most common reason for tumor-associated deaths in 2015, but also in countries in Western and Central Asia. 1,2 Approximately 70%-80% of patients with HCC are diagnosed at terminal stages of the disease. 3 Therefore, many nonsurgical therapies are used, such as transarterial chemoembolization (TACE) and percutaneous radiofrequency ablation (RFA). 4, 5 However, despite these advancements, the morbidity and death rates of HCC are increasing. 6 To achieve precise individualized therapy in patients with HCC, the discovery of appropriate markers for proper prognostic evaluation is urgently needed. Serum markers, with their general availability and affordability, are useful for predicting HCC recurrence and survival. 7 Recently, accumulating evidence has indicated that the systemic inflammatory response (SIR) is pivotal in tumor development. 8 Some proposed inflammatory indicators, including the neutrophil/lymphocyte ratio (NLR), the platelet/lymphocyte ratio (PLR), and the C-reactive protein (CRP) level, have been demonstrated to be useful indicators for evaluating the prognosis of the disease and survival of various cancers. 9, 10 Currently, the CRP/albumin (Alb) ratio (CAR) has been identified as a new prognostic marker. An increased CAR is related to an unfavorable prognosis of various cancers, for example, cervical cancer and esophageal cancer. 11, 12 Nevertheless, whether the CAR is linked to the prognosis in patients with HCC following TACE and RFA is unknown. Therefore, our study examined the prognostic importance of combining the CAR and the NLR in patients with HCC following TACE and RFA. 
| MATERIAL S AND ME THODS

| Patient selection
| TACE procedure
For TACE, the hepatic artery was catheterized via the right common femoral artery under fluoroscopic guidance. The tumor-feeding artery was then identified by common hepatic and superior mesenteric arteriography. A mixture of pirarubicin (15 mg/m 2 ), hydroxycamptothecin (8 mg/m 2 ), and lipiodol (5-10 mL) was administered under the control of a fluoroscope until arterial flow stasis was evident.
| RFA procedure
Radiofrequency ablation was performed on an inpatient basis using an internal cooling rheophore with a 2-or 3-cm exposed tip (Olympus Winter & Ibe GmbH). After the administration of general or local anesthetics, electrode needles were inserted into the tumor percutaneously under contrast-enhanced computed tomography (CT) guidance.
The procedures were performed according to the standard technique.
Tumor ablation was then performed until the cancer was completely removed, avoiding the intrahepatic bile duct and large vessels. The needle tract was also ablated to stop bleeding and prevent tract seeding. All patients received RFA treatment within 1 week after TACE.
| Data collection
Data were collected at the time of diagnosis and included patient demographics, tumor size (cm), tumor number, Child-Pugh class, the presence of liver cirrhosis, portal vein tumor emboli, Barcelona Clinic Liver Cancer (BCLC) stage, the serum Alb level (g/dL), the CRP level (mg/dL), the serum alpha-fetoprotein (AFP) level (ng/dL), the complete blood count, and other clinicopathologic parameters.
As described previously, 15 the Glasgow Prognostic Score (GPS) consists of two biochemical indices, namely the CRP level (≤10 mg/L: 0, >10 mg/L: 1) and the Alb level (≥35 g/L: 0, <35 g/L: 1). The sums of the scores of the three groups were 0, 1, or 2. The CAR was defined as the CRP/Alb ratio. The lymphocyte/monocyte ratio (LMR) was defined as the lymphocyte/monocyte ratio. The NLR and the PLR were 
| Statistical analysis
Statistical analyses were performed using IBM SPSS 22.0 statistical software (SPSS Inc). Variables with significant prognostic value according to the Kaplan-Meier analysis were included in the multivariate analysis via Cox regression analysis, which was conducted with the backward step method. Survivorship curves were calculated using the Kaplan-Meier method and examined by log-rank tests. Comparisons of the differences between groups were tested for significance with chi-squared tests for classified variables. The optimal cutoff values for inflammation-based prognostic scores were determined via receiver operating characteristic (ROC) curve analysis. The associations between the CAR and other inflammation-based prognostic markers, for instance, the NLR and the LMR, were analyzed by Spearman's rank correlations.
The survival curves and ROC curves were generated via GraphPad Prism 6.0 (GraphPad Software Inc). Two-sided P-values < .05 were deemed statistically significant. The baseline characteristics of all 172 patients are listed in Table 1 .
| RE SULTS
| Patient characteristics
| Optimal cutoff values
Receiver operating characteristic curve analysis identified the recom- 
| Survival and prognostic factors
According to the univariate analysis, the tumor size (HR = 1.378 CI: After multivariate Cox regression analysis, the tumor size (HR = 1.561, CI: 1.256-1.941, P = .006), presence of portal vein thrombosis (HR = 1.712, CI: 1.420-2.062, P = .001), GPS (HR = 1.757, CI: 1.604-1.925, P = .01), CAR (HR = 3.167, CI: 2.588-3.876, P = .001), and NLR (HR = 1.912, CI: 1.713-2.134, P = .003) were all found to be independent prognostic factors of OS in patients with HCC (Table 1; Figure 2).
| Relationships of the GPS and CAR to other clinicopathological factors
Significant correlations were found between the two GPS (0/1-2) groups and liver cirrhosis (P = .003), the tumor number (P = .02), the Child-Pugh grade (P = .001), the PLR (P = .006), and the LMR (P = .021; Table 2 ). In addition, the correlation analysis revealed that an elevated CAR was significantly related to tumor size (P = .019), AFP level (P = .033), the presence of portal vein thrombosis (P = .004), the NLR (P = .036), and the LMR (P = .001; Table 2 ). Figure 5 ; Table 1 ).
| D ISCUSS I ON
Accumulating evidence indicates that outcomes for patients with cancer are significantly associated with the level of tumor-associated inflammation. 16 When the growth or invasion of tumors occurs, inflammatory cytokines, for instance, tumor necrosis factor (TNF); interleukin (IL)-6, and −8; and vascular endothelial all growth factor (VEGF), are secreted by cancer cells or tumor-associated lymphocytes, which facilitates angiogenesis and the inhibition of the host immunoreaction, including that involving neutrophils, lymphocytes, platelets, and CRP. 17, 18 Therefore, elevated levels or ratios of inflammatory cells could represent important independent patient-correlated factors associated with the prognosis of various cancers. 19, 20 Among these inflammatory markers, elevated serum CRP levels could indicate that the acute-stage inflammatory response is induced by hepatocytes and regulated by systemic inflammatory cytokines, especially IL-6. 21 Maeda et al demonstrated that IL-6 may be an important regulator of invasion in HCC. 22 Moreover, elevation of CRP levels is accompanied by malnutrition, leading to increased mortality in patients with cancer. 23 In addition, neutrophilia may promote VEGF release and the progression of cancer. A reduced number of lymphocytes also reflect impairment of host antitumor immunity. 24 TA B L E 1 The prognostic value of pretreatment inflammatory factors for overall survival identified by univariate and multivariate analyses in hepatocellular carcinoma patients In this study, multivariate analysis revealed that the CAR, which is thought to be a low-cost prognostic inflammatory marker, as well as the GPS and the NLR were markedly associated with the prognosis of malignant tumors in patients with HCC. Akiyoshi Kinoshita et al also reported that the CAR could predict recurrence after therapy. 25 When the CAR and NLR were combined, the lowest OS rate was found for patients with HCC in the CAR-High and NLR-High cohort. These results further support that HCC is associated with the SIR and malnutrition, with subsequent poor survival rates.
Our results indicated that combining the CAR with the NLR was a useful index. Based on the ROC curve analysis, the AUC of the combined CAR and NLR was larger than those of either the CAR or NLR alone. These findings further indicated that a positive relationship exists between the CAR and NLR with respect to predicting the prognosis. The combination of the CAR and the NLR, which are based on inflammatory biomarkers, was more useful for the prediction of the prognosis of patients with HCC than either the CAR or the NLR alone. 12, 26 In addition, this conclusion demonstrated that There were several limitations of our study. First, because of our study was retrospective, bias may have been unavoidable. In particular, most patients participated in this study from January 2009 to be partly attributed to accompanying liver cirrhosis in patients with HCC in our cohort. 25, 27 Hence, our results need to be confirmed in future large-sized, randomized, controlled validation studies.
In addition to demonstrating the prognostic ability of inflam- are associated with the growth or invasion of tumors in various cancers, including HCC. 21, 22 (c) Neutrophilia can promote the release of VEGF. Lymphocytopenia also reflects an impairment in host antitumor immunity. 24 In addition, platelets can prompt the secretion of several types of growth factors, such as tumor growth factor-beta and VEGF. 28 Although the GPS and the CAR utilize the same factors, the CAR predicts the prognosis of HCC more accurately than the GPS because it is a continuous variable. Moreover, Kinoshita has suggested that the GPS could misestimate the prognostic ability of inflammation-related factors, as it scores CRP and serum Alb values separately. 25 In contrast, the CAR is defined as the ratio of the CRP and serum Alb levels, thus reducing the potential for overestimating or underestimating the prognostic ability of the individual markers in patients with HCC. Furthermore, the CAR has a much stronger prognostic ability than the GPS in pancreatic cancer 26, 29 and patients with HCC. 25 In summary, our study showed that the CAR is a simple, accurate, inexpensive, and convenient predictor of the prognosis of patients with HCC. Moreover, combining the NLR and the CAR results in a convenient, quick, and noninvasive biological marker that can effectively predict the prognosis of patients with HCC.
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